John Oyler, Chief Executive Officer at BeOne Medicines Ltd. (ONC), sold 109,713 shares at $310.08 ($34.6M) on 2026-07-20, disclosed to the SEC on 2026-07-22.
Scheduled sale ($34.6M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $310.08 | 5,146 | $1.6M | 4.6% |
| 2 | $310.75 | 6,273 | $1.9M | 5.6% |
| 3 | $311.80 | 2,907 | $906K | 2.6% |
| 4 | $312.29 | 15,499 | $4.8M | 14.0% |
| 5 | $312.96 | 14,326 | $4.5M | 13.0% |
| 6 | $313.91 | 1,850 |
| $581K |
| 1.7% |
| 7 | $315.26 | 1,512 | $477K | 1.4% |
| 8 | $316.14 | 523 | $165K | 0.5% |
| 9 | $318.30 | 280 | $89K | 0.3% |
| 10 | $316.26 | 15,379 | $4.9M | 14.1% |
| 11 | $316.91 | 20,029 | $6.3M | 18.3% |
| 12 | $318.41 | 7,842 | $2.5M | 7.2% |
| 13 | $319.29 | 15,807 | $5.0M | 14.6% |
| 14 | $320.06 | 2,340 | $749K | 2.2% |
| Total | $315.28 avg | 109,713 | $34.6M | 100% |
| Filing → |
| ONC | SELL | 2026-07-17 | $20.2M | — | Filing → |
| ONC | SELL | 2026-07-14 | $18.3M | — | Filing → |
| ONC | SELL | 2026-07-14 | $44.6M | — | Filing → |